Sheaff Brock Investment Advisors LLC Buys 150 Shares of Novo Nordisk A/S (NYSE:NVO)

Sheaff Brock Investment Advisors LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 4.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,470 shares of the company’s stock after acquiring an additional 150 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $413,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Novo Nordisk A/S by 10.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock valued at $1,102,857,000 after acquiring an additional 823,036 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Novo Nordisk A/S by 1.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock worth $607,242,000 after buying an additional 58,935 shares during the period. GQG Partners LLC increased its position in Novo Nordisk A/S by 654.6% in the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after buying an additional 3,151,584 shares during the period. Raymond James & Associates increased its position in Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after buying an additional 36,223 shares during the period. Finally, 1832 Asset Management L.P. increased its position in Novo Nordisk A/S by 7.8% in the 1st quarter. 1832 Asset Management L.P. now owns 2,373,029 shares of the company’s stock worth $304,697,000 after buying an additional 172,003 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $101.74 on Friday. The stock’s fifty day simple moving average is $118.58 and its 200 day simple moving average is $129.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market cap of $456.56 billion, a price-to-earnings ratio of 32.93, a P/E/G ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15.

Analysts Set New Price Targets

NVO has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.